GTCR Commits Up To $200M To Specialty Pharma Venture

Law360, New York (August 6, 2013, 12:48 PM EDT) -- Chicago private equity firm GTCR will pour up to $200 million into Crealta Pharmaceuticals Inc., a specialty pharmaceuticals upstart with an eye toward climbing to a top spot in the buzzing industry through the acquisition of promising companies and products, it said Tuesday.

GTCR will dip into its 10th fund, one with $3.25 billion in committed capital, to back the new venture, it said.

Crealta was formed through a partnership with pharmaceuticals veteran Ed Fiorentino, the former top executive at Actient Pharmaceuticals LLC, a life sciences...
To view the full article, register now.